Xencor, Inc Increase (Decrease) in Other Operating Assets and Liabilities, Net
Xencor, Inc (XNCR) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $3.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-05
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $1.25M, a 81.26% decline year-over-year.
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $2.39M.
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was $1.11M.
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was -$216.00K.
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was $7.18M.
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was $0.00.
- Xencor, Inc increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.64M 10-Q · filed 2026-08-05 | $4.75M derived: sum of 3 quarters · filed 2026-08-05 | $4.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.39M 10-Q · filed 2026-05-06 | $3.50M derived: sum of 2 quarters · filed 2026-05-06 | $3.28M derived: sum of 3 quarters · filed 2026-05-06 | $9.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $890.00K derived: sum of 2 quarters · filed 2026-02-25 | $7.54M derived: sum of 3 quarters · filed 2026-08-05 | $7.18M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.44M derived: sum of 2 quarters · filed 2026-08-05 | $6.07M 10-Q · filed 2025-11-05 | $178.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $6.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.29M 10-Q · filed 2026-08-05 | $394.00K derived: sum of 3 quarters · filed 2026-08-05 | $394.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$368.00K 10-Q · filed 2026-05-06 | -$6.26M derived: sum of 2 quarters · filed 2026-05-06 | -$6.26M derived: sum of 3 quarters · filed 2026-05-06 | -$368.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$5.89M derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.89M derived: sum of 2 quarters · filed 2025-11-05 | $5.89M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $5.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.89M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |